Meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and preparation method thereof

A nano drug carrier, mesoporous silicon technology, applied in the field of medical materials, can solve the problems of low conversion rate, difficulty in balancing reduction responsiveness and targeting, unsatisfactory drug performance, etc., and achieve low cost and good cell compatibility High performance and versatility

Inactive Publication Date: 2013-03-06
CHONGQING UNIV
View PDF0 Cites 37 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, in the field of preparation of mesoporous silicon nanomaterial drug carriers, due to technical reasons, it is often difficu...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and preparation method thereof
  • Meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and preparation method thereof
  • Meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] This embodiment mainly includes the following steps:

[0031] a. Monodisperse mesoporous silicon nanoparticles prepared by sol-gel and template method;

[0032] b. Using 3-aminopropylsilane coupling agent to modify the mesoporous silicon nanoparticles obtained in step a to prepare aminated mesoporous silicon nanoparticles;

[0033] c. Using succinic anhydride to react with the aminated mesoporous silicon nanoparticles obtained in step b to prepare carboxylated mesoporous silicon nanoparticles;

[0034] d. Using cystamine molecules (rich in disulfide bonds) to functionalize the carboxylated mesoporous silicon nanoparticles obtained in step c to prepare disulfide bond-modified mesoporous silicon nanoparticles;

[0035] e. Using the disulfide bond-functionalized mesoporous silicon nanoparticles obtained in step d of collagen molecule blocking to prepare a mesoporous silicon / collagen molecule reduction-responsive nanocomposite system;

[0036] f. Using the mesoporou...

Embodiment 2

[0050] This example prepares the preparation of mesoporous silicon / collagen-lactobionic acid multifunctional nanocomposite particles with both reduction responsiveness and targeting.

[0051] Including the following steps: a. Synthesis of mesoporous silicon nanoparticles: First, 1 g of cetyltrimethylammonium bromide and 0.28 g of sodium hydroxide were uniformly dispersed in 480 mL of distilled water, vigorously stirred and heated to 80 °C. Add 5 g tetraethyl orthosilicate dropwise to the above solution with a uniform injector, and stir vigorously for 2 h until the mixture becomes a white suspension. Then, the prepared mesoporous silicon nanomaterials with surfactants (CTABMSNs) were uniformly dispersed in 150 mL of methanol / hydrochloric acid (135 mL: 15 mL) mixture. After vigorous stirring, the above solution was refluxed in a water bath at 80°C for 48 hours to effectively extract the surfactant (CTAB) and obtain mesoporous silica nanoparticles (MSNs) with regular pore struct...

Embodiment 3

[0059] This example, as the first experimental example of the present invention, studies the reduction-responsive behavior of mesoporous silicon / collagen-lactobionic acid multifunctional nanocomposite particles.

[0060] In this study, FITC was used as a model drug to investigate the reduction-responsive release characteristics of the mesoporous silica / collagen-lactobionic acid composite system.

[0061] First, the present invention investigates the effect of threothiobiitol (DTT) on the release behavior of the nanocomposite system. The specific experimental process is as follows: two groups of 3.3 mg FITC-labeled mesoporous silica / collagen-lactobionic acid particles and 3.3 mg collagen-adsorbed mesoporous silica nanoparticles were dissolved in 3 mL of PBS, and loaded with 30 mg and 0 mg respectively. and 30 mg of DTT to make three mixed solutions. Then, all the above mixed liquid was transferred to a dialysis bag (molecular weight greater than 14,000), placed in a container ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Specific surface areaaaaaaaaaaa
Specific surface areaaaaaaaaaaa
Login to view more

Abstract

The invention discloses a meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and a preparation method thereof. Firstly, meso-porous silicon nano-particles are prepared with a sol-gel method, and are developed into a nanometer reservoir of drug molecules; then a disulfide bond is introduced into the surface of the meso-porous silicon nanometer reservoir with a simple chemical modification method and is used as a cohesive tie; secondarily, a biocompatible natural extracellular matrix-collagen molecule is creatively fixed to the surface of the meso-porous silicon nanometer reservoir and is developed into a nanometer encapsulator of the meso-porous silicon nanometer reservoir; and finally a lactobionic acid molecule is modified to the surface of a meso-porous silicon/collagen nanometer compounding system and is used as a specificity receptor of a liver cancer cell membrane surface receptor (ASGP-R) so as to construct a meso-porous silicon/collagen-lactobionic acid multifunctional compound type nano-drug carrier system with both cell specificity targeting ability and reducing substance/enzyme responsiveness.

Description

technical field [0001] The invention belongs to the field of medical materials, and relates to a method for constructing a multifunctional medical nanocarrier. Background technique [0002] After more than half a century of exploration and development, the intelligent drug controlled release system has fully demonstrated its potential application value in the medical field. Controlled-release drug delivery has gradually become an important branch of biomedical research, which spans multiple interdisciplinary disciplines such as engineering technology, tissue engineering, biomaterials, and clinical medicine. The microelectromechanical drug delivery system pioneered by Robert Langer et al. utilizes external remote signals to realize the controlled release of the system in vivo. However, the drug molecules released by the system cannot specifically recognize the target cells, and most of the drug molecules are distributed in normal tissues and taken up by normal cells; while t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/04A61K47/26A61K47/42A61K9/14A61P35/00
Inventor 蔡开勇罗忠胡燕张蓓露
Owner CHONGQING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap